Deciphera surges on Q3 revenue beat

Deciphera Pharmaceuticals

30/10/2023 12:33

** Shares of cancer drug developer Deciphera Pharmaceuticals
 DCPH.O  rise 20.4% to $12.22 premarket
        ** Co's quarterly revenue of $43.3 mln beats analysts'
average expectation of $39.4 mln 
    ** DCPH's lead medication Qinlock, which treats a type of
stomach cancer, increased quarterly sales by 29% from a year
earlier 
    ** Co reports Q3 loss of 58 cents/shr vs analysts' average
loss estimate of 61 cents/shr - LSEG data
    ** Up to last close, shares down 38.1% this year

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))